{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:33:36Z","timestamp":1792042416343,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008468","name":"Canadian Urological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012317","name":"Astellas Pharma Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003122","name":"Ferring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003122","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41391-020-00288-y","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T19:11:47Z","timestamp":1601320307000},"page":"389-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE\u2212\/\u2212:Ins2+\/Akita mouse model"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3439-9163","authenticated-orcid":false,"given":"Wilhelmina C. M.","family":"Duivenvoorden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Naeim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah N.","family":"Hopmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff H.","family":"Werstuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Dason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehonathan H.","family":"Pinthus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"288_CR1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1180::AID-CNCR18>3.0.CO;2-1","volume":"83","author":"WA Satariano","year":"1998","unstructured":"Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998;83:1180\u20138.","journal-title":"Cancer"},{"key":"288_CR2","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.ju.0000127740.96006.1a","volume":"171","author":"G Lu-Yao","year":"2004","unstructured":"Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171:2285\u201390.","journal-title":"J Urol"},{"key":"288_CR3","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1056\/NEJMsa0910784","volume":"363","author":"VB Shahinian","year":"2010","unstructured":"Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363:1822\u201332.","journal-title":"N Engl J Med"},{"key":"288_CR4","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448\u201356.","journal-title":"J Clin Oncol"},{"key":"288_CR5","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai HK, D\u2019Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516\u201324.","journal-title":"J Natl Cancer Inst"},{"key":"288_CR6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493\u20131500.","journal-title":"Cancer"},{"key":"288_CR7","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","volume":"28","author":"M Van Hemelrijck","year":"2010","unstructured":"Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol. 2010;28:3448\u201356.","journal-title":"J Clin Oncol"},{"key":"288_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"288_CR9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","volume":"367","author":"JM Crook","year":"2012","unstructured":"Crook JM, O\u2019Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl J Med. 2012;367:895\u2013903.","journal-title":"N. Engl J Med"},{"key":"288_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565\u201373.","journal-title":"Eur Urol"},{"key":"288_CR11","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","volume":"202","author":"D Margel","year":"2019","unstructured":"Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate Cancer and preexisting cardiovascular disease. J Urol. 2019;202:1199\u20131208.","journal-title":"J Urol"},{"key":"288_CR12","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.urolonc.2014.06.018","volume":"32","author":"SN Hopmans","year":"2014","unstructured":"Hopmans SN, Duivenvoorden WCM, Werstuck GH, Pinthus J. GnRH antagonists associate with less weight gain and milder characteristics of the metabolic syndrome compared to orchiectomy and GnRH agonists in a preclinical mouse model. Urol Oncol. 2014;32:1126\u201334.","journal-title":"Urol Oncol"},{"key":"288_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep26220","volume":"6","author":"A Knutsson","year":"2016","unstructured":"Knutsson A, Hsiung S, Celik S, Rattik S, Mattisson IY, Wigren M, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-\/-) mice. Sci Rep. 2016;6:26220.","journal-title":"Sci Rep."},{"key":"288_CR14","unstructured":"FDA Drug Safety Communication: Update to Ongoing Safety Review of GnRH Agonists and Notification to Manufacturers of GnRH Agonists to Add New Safety Information to Labeling Regarding Increased Risk of Diabetes and Certain Cardiovascular Diseases. 2010; https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-update-ongoing-safety-review-gnrh-agonists-and-notification. Accessed 12 April 2020."},{"key":"288_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.juro.2006.03.057","volume":"176","author":"J Yannucci","year":"2006","unstructured":"Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176:520\u20135.","journal-title":"J Urol"},{"key":"288_CR16","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","volume":"24","author":"M Braga-Basaria","year":"2006","unstructured":"Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979\u201383.","journal-title":"J Clin Oncol"},{"key":"288_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s11764-009-0114-1","volume":"4","author":"F Haseen","year":"2010","unstructured":"Haseen F, Murray LJ, Cardwell CR, O\u2019Sullivan JM, Cantwell MM. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv. 2010;4:128\u201339.","journal-title":"J Cancer Surviv"},{"key":"288_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599\u2013603.","journal-title":"J Clin Endocrinol Metab"},{"key":"288_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.critrevonc.2008.06.006","volume":"68","author":"GJ van Londen","year":"2008","unstructured":"van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan SL. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol. 2008;68:172\u20137.","journal-title":"Crit Rev Oncol Hematol"},{"key":"288_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.jrn.2004.09.009","volume":"15","author":"G Biolo","year":"2005","unstructured":"Biolo G, Ciocchi B, Stulle M, Piccoli A, Lorenzon S, Dal Mas V, et al. Metabolic consequences of physical inactivity. J Ren Nutr. 2005;15:49\u201353.","journal-title":"J Ren Nutr"},{"key":"288_CR21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/ajcn\/85.3.662","volume":"85","author":"MP Corcoran","year":"2007","unstructured":"Corcoran MP, Lamon-Fava S, Fielding RA. Skeletal muscle lipid deposition and insulin resistance: effect of dietary fatty acids and exercise. Am J Clin Nutr. 2007;85:662\u201377.","journal-title":"Am J Clin Nutr"},{"key":"288_CR22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1210\/jc.2005-2507","volume":"91","author":"MR Smith","year":"2006","unstructured":"Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"288_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2006.09.032","volume":"49","author":"AS Gami","year":"2007","unstructured":"Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"288_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/JU.0000000000000714","volume":"203","author":"DP Leong","year":"2020","unstructured":"Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203:1109\u201316.","journal-title":"J Urol"},{"key":"288_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1172\/JCI4431","volume":"103","author":"J Wang","year":"1999","unstructured":"Wang J, Takeuchi T, Tanaka S, Kubo SK, Kayo T, Lu D, et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J Clin Invest. 1999;103:27\u201337.","journal-title":"J Clin Invest"},{"key":"288_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ajpath.2015.09.009","volume":"186","author":"DE Venegas-Pino","year":"2016","unstructured":"Venegas-Pino DE, Wang PW, Stoute HK, Singh-Pickersgill NA, Hong BY, Khan MI, et al. Sex-specific differences in an ApoE(-\/-):Ins2(+\/Akita) mouse model of accelerated atherosclerosis. Am J Pathol. 2016;186:67\u201377.","journal-title":"Am J Pathol"},{"key":"288_CR27","doi-asserted-by":"publisher","first-page":"e002800","DOI":"10.1161\/JAHA.115.002800","volume":"5","author":"CB Poulsen","year":"2016","unstructured":"Poulsen CB, Mortensen MB, Koechling W, Sorensen CB, Bentzon JF. Differences in hypercholesterolemia and atherogenesis induced by common androgen deprivation therapies in male mice. J Am Heart Assoc. 2016;5:e002800.","journal-title":"J Am Heart Assoc"},{"key":"288_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/CMAR.S16893","volume":"3","author":"H Van Poppel","year":"2011","unstructured":"Van Poppel H, Tombal B. Cardiovascular risk during hormonal treatment in patients with prostate cancer. Cancer Manag Res. 2011;3:49\u201355.","journal-title":"Cancer Manag Res"},{"key":"288_CR29","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1194\/jlr.M600146-JLR200","volume":"47","author":"L Wu","year":"2006","unstructured":"Wu L, Vikramadithyan R, Yu S, Pau C, Hu Y, Goldberg IJ, et al. Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis. J Lipid Res. 2006;47:2215\u201322.","journal-title":"J Lipid Res"},{"key":"288_CR30","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1172\/JCI117179","volume":"93","author":"S Ishibashi","year":"1994","unstructured":"Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994;93:1885\u201393.","journal-title":"J Clin Invest"},{"key":"288_CR31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0092-8674(92)90362-G","volume":"71","author":"AS Plump","year":"1992","unstructured":"Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343\u201353.","journal-title":"Cell"},{"key":"288_CR32","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1411543","volume":"258","author":"SH Zhang","year":"1992","unstructured":"Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468\u201371.","journal-title":"Science"},{"key":"288_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2337\/db06-0144","volume":"56","author":"J Gao","year":"2007","unstructured":"Gao J, Katagiri H, Ishigaki Y, Yamada T, Ogihara T, Imai J, et al. Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes. 2007;56:24\u201333.","journal-title":"Diabetes"},{"key":"288_CR34","doi-asserted-by":"publisher","first-page":"E145","DOI":"10.1152\/ajpendo.00034.2011","volume":"301","author":"JY Jun","year":"2011","unstructured":"Jun JY, Ma Z, Segar L. Spontaneously diabetic Ins2(+\/Akita):apoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis. Am J Physiol Endocrinol Metab. 2011;301:E145\u201354.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"288_CR35","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531\u20138.","journal-title":"BJU Int"},{"key":"288_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.atherosclerosis.2018.05.044","volume":"275","author":"DE Venegas-Pino","year":"2018","unstructured":"Venegas-Pino DE, Lagrotteria A, Wang PW, Morphet J, Clapdorp C, Shi Y, et al. Evidence of extensive atherosclerosis, coronary artery disease and myocardial infarction in the ApoE(-\/-):Ins2(+\/Akita) mouse fed a western diet. Atherosclerosis. 2018;275:88\u201396.","journal-title":"Atherosclerosis"}],"updated-by":[{"DOI":"10.1038\/s41391-021-00408-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-00288-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-00288-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-00288-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:50:25Z","timestamp":1723683025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-00288-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["288"],"URL":"https:\/\/doi.org\/10.1038\/s41391-020-00288-y","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41391-021-00408-2","asserted-by":"object"}]},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41391-021-00408-2","URL":"https:\/\/doi.org\/10.1038\/s41391-021-00408-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JHP has acted in a consulting role for Ferring Pharmaceuticals; has received research funding for projects from Ferring Pharmaceuticals. The remaining authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}